Unique HTS Support and Library Curator Services

LCGC accelerates screening from assay validation to nascent lead-candidate nomination. We provide assay ready screening plates from our own (proprietary) or your own library (or both, see below). We can format the compounds for orthogonal pooled screening (HTS-OPS). We ship the assay-ready plates back to your lab for screening; your technician simply adds the reagents, incubates and then reads. Just send us the raw results in the form of electronic data and LCGC will perform a full analysis with our proprietary de-convolution software and send you results, including an SAR table from our library samples. We provide you cherry-picks for confirmation retesting via our patented NARS. Let us curate your own collection in our NARS and accelerate your HTS campaigns while markedly reducing costs. Accelerate and enhance your HTS abilities - instantly, at reasonable cost - guaranteed. All IP is protected by stringent confidentiality; besides, we need never know your target details to provide these services.

• 　　　Our proprietary chemical libraries are offered in the orthogonal pooled screening format (HTS-OPS) on an annual subscription basis. Pay only for the samples you actually screen; from one screen to dozens per year (unique approach).
• 　　　We use our proprietary data analysis software to de-convolute the raw or normalized data your lab sends us electronically and we send back the structure-activity relationship (SAR) table.
• 　　　You select what should be retested. We then cherry-pick the actives from the very same DMSO stocks used in HTS with our NanoTube Automated Repository System (NARS), which can store and rapidly retrieve more than 10-million individually frozen compounds ('single-shot'). Importantly, no compound is ever freeze-thawed, which provides the highest quality assurance for HTS confirmation re-testing.
• 　　　We will serially dilute the picks to your specifications and even add reference and control compounds, and then send back assay-ready plates for your determination of potency and selectivity. You may create focused screening sets 'on-the-fly' to more deeply mine SAR.
• 　　　All IP is assured, since we do not require, or desire, any information on your target, although we execute a CDA with all our collaborators.
• 　　　Let us curate your own collection in our NARS and accelerate your HTS campaigns while markedly reducing costs. Double your HTS abilities梚nstantly, at far lower cost.
• 　　　Once you try the LCGC model, you may not go back to the drudgery of manual compound management, nor will your precious research assets deteriorate from freeze-thaw cycling

Pharma Services

Enter a totally new public-private partnering paradigm
Among the pharmaceutical industry's most important resources are the chemically diverse compound libraries. But the vast majority of them are not utilized to their greatest potential, causing poor monetization of the company's valuable assets. Double-Blinded Drug Discovery® helps TA teams extract greater value from these assets quickly and cost effectively. The TA Head approves the distribution of 'library snapshots' to academic scientists for target validation by HTS. LCGC's proprietary technologies permit chemical collections to become safely distributed and screened in a compressed, veiled format that preserves structural integrity and privacy.
LCGC also provides ultra-low-cost storage and distribution of chemical collections to internal research teams at worldwide sites and subsidiaries, or to the company's network of CROs. Our innovative research-materials management systems and compound formatting services are unavailable elsewhere. LCGC offers extremely cost-effective and IP-secure services that will deliver: 1) higher quality of data; 2) accelerated program progression; 3) R&D cost reduction; 4) secure and disaster-proof backup with redundancy for internal compound management operations to increase speed of delivery to TAs.

Academia Services

Benefit from a totally new public-private partnering model
LCGC's protected open-innovation model amplifies translation research ability for the PI using HTS to validate novel target pathways. We provide no-cost access to highly curated collections of drug-filtered, diverse small molecules that have been carefully compiled over decades by the experienced medicinal and computational chemists in industry. Our approach provides new opportunities for out-licensing IP by the TTO and sponsored R&D funding for the PI to advance discoveries from screening made in the home lab or the HTS core. LCGC's own proprietary compound library allows researchers full publication rights. Discover 'druggable' new leads with true licensure value and clear-path development tracks faster by a new way for screening the highest quality structures in pharma's vast chemical collections that are available now.

Compound Libraries

In addition to the NARS repository, LCGC has acquired a unique compound library of 104,000 members, with powder reserves of 10 mg each. The file was acquired with a unique computational and 'medicinal bias' that differs from a typical approach. These compounds pass all Lipinski and drug reactivity filters typically used in pharma to qualify drug-like libraries for high throughput screening (HTS). Creation of focused libraries is easily accomplished for thousands of compounds in days, rather than weeks. Clients have the opportunity to capture IP and produce publications even if a pharmaceutical 'hit' is not revealed